UNIGE document Scientific Article
previous document  unige:33832  next document
add to browser collection

Place des bêta-agonistes de longue durée dans le traitement de l'asthme bronchique

Published in Revue Médicale Suisse. 2008, vol. 4, no. 175, p. 2203-4,2206-7
Abstract Long acting beta2-agonists (LABA) are one of the most widely prescribed anti-asthmatic therapies. Nevertheless, their chronic utilization has been associated in large clinical studies with severe asthma exacerbations and asthma-related deaths raising concern about their safety. Awaiting further evidence to definitely identify susceptible subgroups, LABA should be used with caution. Inhaled corticosteroids (ICS) is the preferred asthma controller option and LABA should be used only in association with ICS in patients insufficiently controlled under ICS therapy.
Keywords Adrenal Cortex Hormones/therapeutic useAdrenergic beta-Agonists/therapeutic useAsthma/drug therapyClinical Trials as TopicHumans
PMID: 19024574
Full text
Article (Published version) (221 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Other version: http://rms.medhyg.ch/numero-175-page-2203.htm
(ISO format)
MARTI, Christophe, JANSSENS, Jean-Paul, RUTSCHMANN, Olivier Thierry. Place des bêta-agonistes de longue durée dans le traitement de l'asthme bronchique. In: Revue médicale suisse, 2008, vol. 4, n° 175, p. 2203-4,2206-7. https://archive-ouverte.unige.ch/unige:33832

420 hits

0 download


Deposited on : 2014-01-29

Export document
Format :
Citation style :